COMMUNIQUÉS West-GlobeNewswire

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
14/08/2026
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced [...]
Pfizer et Valneva annoncent l’acceptation pour revue par l’Agence européenne des médicaments (EMA) de la demande d’autorisation de mise sur le marché de leur candidat vaccin contre la maladie de Lyme
14/08/2026
Cette soumission repose sur les résultats positifs d’efficacité et de sécurité de l’étude de Phase 3 VALOR NEW YORK & LYON, France, le 14 août 2026, Pfizer Inc. (NYSE: PFE) et Valneva SE (Nasdaq: VALN; Euronext [...]
Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
14/08/2026
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, [...]
More Cancer Patients Are Opting to Preserve Their Tumors
14/08/2026
New Tumor-Preservation Service Opens in Arizona, Giving Patients the Opportunity to Preserve Unadulterated Tumor Tissue for Potential Personalized Cancer Immunotherapy SCOTTSDALE, Ariz., Aug. 13, 2026 (GLOBE NEWSWIRE [...]
Nutraville Announces MemoryFuel Launch as Interest Grows Around Creatine Monohydrate, Brain Energy, and Daily Mental Performance
14/08/2026
Tallmadge, OH, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutraville has announced the launch of MemoryFuel, a caffeine-free brain-health powder formulated for adults interested in supporting memory, focus support, mental [...]
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
13/08/2026
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic [...]
BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026
13/08/2026
MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on [...]
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
13/08/2026
Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regeneration Continued favorable safety and tolerability profile, [...]
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
13/08/2026
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined [...]
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial [...]
Maze Therapeutics Announces Appointments to Its Board of Directors
13/08/2026
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 ( [...]
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
13/08/2026
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the [...]
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing [...]
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
13/08/2026
– Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash – – July monthly Zola ® sales top $740K; exceed $1 [...]
Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
13/08/2026
The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction [...]
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
13/08/2026
$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix [...]
PetMeds® Announces First Quarter Financial Results
13/08/2026
DELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026. [...]
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with [...]
SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results
13/08/2026
Net Asset Value ("NAV") of $62.9 million , or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share 1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricted Cash, $65.2 million [...]

Pages